查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984173

分子肿瘤诊断市场：2026-2032年全球市场预测（按产品类型、技术、癌症类型、检体类型、应用和最终用户划分）

Molecular Oncology Diagnostics Market by Product Type, Technology, Cancer Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，分子肿瘤诊断市场价值将达到 22.3 亿美元，到 2026 年将成长至 28.5 亿美元，到 2032 年将达到 141.1 亿美元，复合年增长率为 30.13%。

主要市场统计数据
基准年 2025 22.3亿美元
预计年份：2026年 28.5亿美元
预测年份 2032 141.1亿美元
复合年增长率 (%) 30.13%

针对分子肿瘤诊断的简明策略框架，重点在于相关人员在临床整合方面所面临的挑战和创新重点。

分子肿瘤诊断领域正经历着策略重组，其驱动力来自于技术的快速成熟、临床实践的演进以及医疗体系优先事项的转变。重组的核心在于弥合基因组学见解与临床应用之间的鸿沟，从而实现更早期的疾病检测、更精准的治疗方法选择以及对疾病动态的持续监测。诊断创新不仅限于检测灵敏度，还涵盖工作流程整合、数据解读以及将分子特征转化为临床医生可以放心使用的治疗方案。

技术融合、监管调整和商业性合作如何从根本上改变临床引入和产品差异化的路径。

多项变革正在重塑分子肿瘤诊断在研究、临床实践和商业管道中的价值交付方式。首先，高通量定序技术与先进生物资讯学的融合提高了肿瘤谱分析的精细度，使临床医生能够摆脱基于单一标誌物的决策模式，并利用复杂的基因组特征来辅助治疗方法的选择和监测。其次，微创检测正从概念验证阶段走向常规临床应用，加速疾病的长期监测，并实现復发和抗药性机制的早期发现。

针对 2025 年美国关税调整，我们的营运和策略应对措施是重组我们的采购、製造地和采购风险管理。

美国近期推出的关税措施以及针对2025年的贸易政策调整，正在为支持分子肿瘤诊断的全球供应链带来明显的摩擦。仪器製造、试剂配製和耗材生产所需的关键组件通常依赖海外采购，而关税结构的变化推高了进口原材料的成本，同时也促使供应商重组。这一趋势迫使诊断试剂製造商和检查室营运商重新评估供应商多元化、库存策略和合约条款，以保障利润率并避免检测能力中断。

透过对产品、技术、测试、应用、癌症类型、最终用户和检体类型进行多方面的细分，可以确定策略性产品设计和临床实施路径。

细分市场分析表明，产品差异化日益取决于仪器、试剂/试剂盒和软体/服务之间的相互作用。具体而言，仪器支援检查室工作流程，试剂/试剂盒确保检测的特异性，而软体/服务则提供解读的广度和监管可追溯性。技术选择对临床路径有显着影响。萤光杂合反应(FISH) 和免疫组织化学在标靶应用中仍然至关重要，微阵列继续为特定的研究和转化应用做出贡献，而即时PCR提供快速且精准的分析。次世代定序(NGS) 因其广度和深度而脱颖而出。在 NGS 中，标靶定序、全外显EXOME定序和全基因测序各自提供不同的临床和研究效用，而标靶定序本身又进一步分为综合性 panel 和热点聚焦 panel。这些 panel 分别针对广谱、可操作的突变发现或精简的、以临床为导向的突变检测进行了最佳化。

影响监管参与、商业化模式和跨国业务扩张的区域策略差异和实施重点。

区域趋势表明，美洲、欧洲、中东和非洲以及亚太地区在优先事项和业务需求方面存在差异，这影响诊断开发人员和实验室如何制定监管策略、伙伴关係模式和服务交付方式。在美洲，临床和商业活动通常专注于将诊断整合到既定的肿瘤治疗路径中，并与寻求明确临床效用证据的保险公司协商保险覆盖范围。该地区强调快速临床检验和与治疗药物研发的密切合作，从而推动了诊断提供者和药物开发商之间的合作模式。

诊断药物创新者和检测实验室如何在竞争激烈的分子肿瘤学领域中脱颖而出，制定竞争定位和伙伴关係策略。

分子肿瘤诊断领域的竞争动态由成熟的仪器供应商、专业的检测方法开发公司、检查室网路以及新兴的数位分析平台共同塑造。主要企业凭藉检验的分析性能、可重复的临床级检测方法以及符合监管和检查室认证标准的完善品管系统脱颖而出。与製药公司合作开发伴随诊断仍然是获得临床意义的主要途径，这种合作模式能够产生共同的证据，并透过将诊断公司与治疗创新路径结合，推动产品进入临床应用。

为产业领导者提供具有高影响力、可操作的策略行动，以加速临床部署、保护业务营运并增强商业性价值提案。

产业领导者应优先采取一系列切实可行的步骤，将策略意图转化为可衡量的营运成果。首先，他们应投资可互通的数据平台和决策支援工具，以增强基因组分析结果的临床效用，并减轻临床医生的认知负担。这些平台应支援标准化报告，与电子健康记录集成，并提供简洁明了、可操作的解读，供临床医生直接应用于治疗决策。其次，他们应制定模组化的证据策略，将分析检验与真实世界绩效数据结合，从而在满足监管要求和支付方需求的同时，不断完善临床效用价值的论点。

采用透明严谨的调查方法，结合关键相关人员的访谈、二手资料的整合以及基于情境的分析检验。

支持这些研究结果的调查方法结合了证据整合、相关人员参与和严谨的分析检验，以确保其相关性和可靠性。主要研究包括对临床肿瘤学家、实验室经理、诊断试剂开发人员、采购经理和监管顾问进行结构化访谈，以了解第一线观点对临床工作流程、检验预期和采购决策的看法。次要研究则纳入了同行评审的科学文献、最新的临床指南、监管出版物和运营实施案例研究，以阐明主要研究结果的背景并识别新兴技术趋势。

将分析严谨性、临床整合和营运韧性连结起来，并整合策略重点，以最大限度地发挥临床和商业性影响。

总之，分子肿瘤诊断处于技术潜力和临床需求的交会点。要产生切实的影响，仅仅改进检测方法远远不够；我们需要一个整合的解决方案，将分析能力与临床医生的工作流程、循证策略、供应链的韧性以及支付方的期望相协调。那些采用互通资料平台、模组化证据产生方法并与药物研发公司建立策略伙伴关係的机构，将更有能力将基因组学见解转化为常规临床决策。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 分子肿瘤诊断市场：依产品类型划分

  • 装置
  • 试剂和试剂盒
  • 软体服务

第九章 分子肿瘤诊断市场：依技术划分

  • 萤光原位杂合反应
  • 免疫组织化学
  • 微阵列
  • 次世代定序
    • 目标序列
      • 整合面板
      • 热点面板
    • 全EXOME定序
    • 全基因组定序
  • 即时PCR

第十章 依癌症类型分類的分子肿瘤诊断市场

  • 乳癌
  • 结肠癌
  • 白血病
  • 肺癌
  • 摄护腺癌

第十一章 依样本类型分類的分子肿瘤检体市场

  • 基于等离子体
  • 唾液/尿液
  • 组织起源
  • 全血

第十二章 分子肿瘤诊断市场：依应用划分

  • 伴随诊断
  • 早期检测
  • 个人化医疗
  • 预后预测和监测
  • 出于研究目的

第十三章 分子肿瘤诊断市场：依最终用户划分

  • 诊断检测实验室
  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构

第十四章 分子肿瘤诊断市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 分子肿瘤诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 分子肿瘤诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国分子肿瘤诊断市场

第十八章：中国分子肿瘤诊断市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis NV
  • Biocept, Inc.
  • BIOMERIEUX SA
  • Danaher Corporation
  • DiaSorin Molecular LLC
  • Enzo Biochem, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • GenMark Saglik
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina Inc.
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • OncoCyte Corporation
  • PathAI, Inc.
  • Personal Genome Diagnostics Inc.
  • QIAGEN NV
  • Siemens AG
  • Sysmex Asia Pacific Pte Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFE6

The Molecular Oncology Diagnostics Market was valued at USD 2.23 billion in 2025 and is projected to grow to USD 2.85 billion in 2026, with a CAGR of 30.13%, reaching USD 14.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.23 billion
Estimated Year [2026] USD 2.85 billion
Forecast Year [2032] USD 14.11 billion
CAGR (%) 30.13%

A concise strategic framing of the molecular oncology diagnostics domain highlighting clinical integration challenges and innovation priorities for stakeholders

The molecular oncology diagnostics landscape is undergoing a period of strategic realignment driven by rapid technological maturation, evolving clinical practice, and shifting health system imperatives. At its core, the field seeks to close gaps between genomic insight and clinical actionability, enabling earlier detection, more precise therapeutic selection, and continuous monitoring of disease dynamics. Diagnostic innovation is not limited to assay sensitivity; it spans workflow integration, data interpretation, and the translation of molecular signatures into treatment pathways that clinicians can deploy with confidence.

Clinicians, laboratory leaders, and industry stakeholders now face the dual challenge of validating complex assays while ensuring they integrate seamlessly into existing diagnostic and treatment workflows. Adoption depends on reproducible performance, regulatory clarity, and demonstrable utility across diverse patient populations. Meanwhile, payers and health systems increasingly demand evidence of clinical and economic value, prompting diagnostic developers to design studies and evidence packages that respond directly to these decision criteria.

As a result, leaders in molecular oncology diagnostics must balance innovation with pragmatic commercialization strategies. They must invest in robust analytical validation and clinical validation efforts, while also developing clear clinical use cases and data infrastructures that support interpretation and reporting. In this environment, high-quality, timely intelligence about technological trends, clinical adoption patterns, and stakeholder incentives becomes essential for shaping investment, collaboration, and market entry decisions.

How technological convergence, regulatory adaptation, and commercial alliances are fundamentally altering pathways for clinical adoption and product differentiation

Several transformative shifts are reshaping how molecular oncology diagnostics deliver value across research, clinical practice, and commercial channels. First, the convergence of high-throughput sequencing capabilities with advanced bioinformatics has expanded the granularity of tumor profiling, enabling clinicians to move beyond single-marker decisions toward composite genomic signatures that inform therapy selection and monitoring. Second, minimally invasive testing modalities have advanced from proof-of-concept to routine clinical utility, accelerating longitudinal disease monitoring and enabling earlier detection of relapse or resistance mechanisms.

Concurrently, regulatory and reimbursement pathways have become more dynamic, with agencies and payers signaling willingness to engage on evidence frameworks that accommodate innovative diagnostic modalities. This has encouraged more iterative evidence generation strategies that pair real-world data with prospective validation, fostering faster clinical adoption when utility is demonstrable. At the same time, integration of molecular diagnostics into oncology care is catalyzing new commercial partnerships between assay developers, diagnostics laboratories, and therapeutic companies, aligning diagnostic development timelines with drug development and label expansion strategies.

These shifts collectively demand that diagnostic providers focus on scalable laboratory operations, interoperable data platforms, and interpretive algorithms that deliver clinically meaningful, reproducible outputs. Strategic differentiation increasingly rests on end-to-end solutions that combine robust analytic performance with streamlined clinician-facing reports and decision-support tools. As the field evolves, organizations that master both the science and the operational pathways to clinical implementation will capture the greatest long-term value.

Operational and strategic responses to United States tariff adjustments in 2025 that are reshaping sourcing, manufacturing footprints, and procurement risk management

Recent tariff actions and trade policy adjustments in the United States for 2025 have introduced measurable friction into global supply chains that support molecular oncology diagnostics. Components critical to instrument manufacture, reagent formulation, and consumable production are often sourced internationally, and changes in tariff structures raise the cost of imported inputs while incentivizing supplier reconfiguration. This dynamic has prompted diagnostic manufacturers and laboratory operators to reassess supplier diversity, inventory strategies, and contract terms to protect margins and maintain uninterrupted testing capacity.

In response, many organizations have diversified their supplier base, sought local production partnerships, or initiated dual-sourcing strategies to reduce exposure to single-point supply risks. Procurement teams increasingly factor tariff volatility into total cost of ownership calculations, emphasizing end-to-end resilience and lead-time visibility. At the same time, manufacturers are evaluating the feasibility of regionalized manufacturing footprints and selective vertical integration for high-value components to mitigate exposure to trade-related shocks.

The policy-induced changes also influence commercial negotiations, with buyers and vendors renegotiating pricing and service commitments to reflect evolving input costs. For laboratories and health systems, the immediate priority is maintaining access to validated assays and preserving test continuity. For developers and instrument manufacturers, the strategic focus remains on balancing cost containment with the imperative to invest in innovation and quality control. Ultimately, resolving tariff-related disruption requires coordinated operational adjustments and forward-looking sourcing strategies that align with clinical demand and regulatory expectations.

How multi-dimensional segmentation across product, technology, test, application, cancer type, end user, and sample type determines strategic product design and clinical deployment pathways

Segmentation insight reveals that product differentiation is increasingly defined by the interplay between instruments, reagents and kits, and software and services, where instruments anchor laboratory workflows, reagents and kits enable assay specificity, and software and services deliver interpretive scale and regulatory traceability. Technology choices exert a profound influence on clinical pathways: fluorescence in situ hybridization and immunohistochemistry remain essential for targeted applications, microarray continues to serve select research and translational use cases, and real-time PCR provides rapid, focused analyses. Next generation sequencing stands out for breadth and depth; within NGS, targeted sequencing, whole exome sequencing, and whole genome sequencing offer distinct clinical and research utilities, and targeted sequencing itself differentiates into comprehensive panels and hotspot-focused panels, each optimized for either broad actionable variant discovery or streamlined, clinically focused mutation detection.

Test type segmentation shapes service design and clinical value propositions. Liquid biopsy enables minimally invasive longitudinal monitoring, multi-gene panel testing supports simultaneous interrogation of clinically relevant pathways, single gene testing delivers focused actionable results, and whole exome and whole genome approaches provide discovery-oriented breadth that can inform complex or refractory cases. Application-driven strategies must align companion diagnostics with therapeutic pathways, prioritize early detection modalities for population health impacts, and support personalized medicine through prognosis and monitoring tools while addressing research use needs.

Cancer type focus remains a critical lens for clinical relevance, with breast, colorectal, leukemia, lung, and prostate cancer each presenting distinct biomarker landscapes and care pathways that influence assay selection and validation requirements. End users - diagnostic laboratories, hospitals and clinics, pharmaceutical and biotech companies, and research institutes - have divergent operational constraints and purchasing drivers, which necessitates tailored product and service models. Finally, sample type considerations, spanning plasma-based assays, saliva and urine modalities, tissue-based testing, and whole blood analyses, determine pre-analytical workflows and influence analytic sensitivity and specificity. Taken together, these segmentation dimensions require cohesive strategies that link product design, clinical utility, and deployment environments to maximize clinical adoption and operational efficiency.

Regional strategic distinctions and execution priorities that influence regulatory engagement, commercialization models, and cross-border operational scaling

Regional dynamics reveal differentiated priorities and operational imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific, shaping how diagnostics developers and laboratories approach regulatory strategy, partnership models, and service delivery. In the Americas, clinical and commercial activities often center on integrating diagnostics into established oncology care pathways and negotiating coverage with payers that demand clear evidence of clinical utility. This region emphasizes rapid clinical validation and close alignment with therapeutic development, driving collaborative models between diagnostics providers and pharmaceutical developers.

In Europe, the Middle East & Africa, regulatory harmonization and variable reimbursement landscapes prompt stakeholders to design adaptable evidence generation strategies that can address diverse national requirements. Organizations operating across these markets prioritize modular data packages and centralized laboratory services while also engaging local clinical networks to validate utility in region-specific patient populations. The Asia-Pacific region features a mix of large, high-volume healthcare systems and rapidly developing molecular capabilities, encouraging investments in scalable testing platforms, local manufacturing partnerships, and digital reporting systems that support high-throughput workflows.

Transitioning across regions requires sensitivity to differing healthcare financing models, clinician practice patterns, and laboratory infrastructure. Successful market entrants adapt regulatory and commercial approaches to each region's institutional landscape, engage early with local clinical and payer stakeholders, and tailor go-to-market strategies that reflect regional diagnostic adoption curves and operational capacity. Coordinated regional strategies that leverage centralized data insights while accommodating local execution imperatives will be critical for sustained impact.

Competitive positioning and partnership strategies that enable diagnostic innovators and laboratories to differentiate in a crowded molecular oncology landscape

Competitive dynamics in molecular oncology diagnostics are shaped by a mix of established instrument providers, specialized assay developers, laboratory networks, and emerging digital interpretation platforms. Leading players distinguish themselves through validated analytical performance, reproducible clinical-grade assays, and robust quality management systems that satisfy regulatory bodies and laboratory accreditation standards. Collaboration with pharmaceutical developers on companion diagnostics continues to be a primary route to clinical relevance, positioning diagnostic companies alongside therapeutic innovation pathways and enabling joint evidence generation that supports simultaneous clinical adoption.

Smaller, agile firms frequently compete on niche innovations - for example, highly optimized targeted sequencing panels, proprietary sample stabilization chemistries, or interpretive algorithms that improve variant classification and reduce turnaround time. These firms often partner with larger laboratories or engage in licensing deals to scale reach and accelerate clinical deployment. At the same time, laboratory networks and reference testing providers expand their service portfolios by integrating advanced assays and investing in automation and bioinformatics to offer turn-key solutions to health systems and clinical trial sponsors.

Across the competitive landscape, differentiation increasingly relies on end-to-end capabilities that combine analytical excellence with clinician-facing reporting, payer-aligned evidence packages, and operational scalability. Alliances and strategic partnerships remain central to growth strategies, enabling companies to pair technical strengths with distribution channels, reimbursement expertise, and clinical advocacy that drive adoption.

High-impact and implementable strategic actions for industry leaders to accelerate clinical adoption, safeguard operations, and strengthen commercial value propositions

Industry leaders should prioritize a set of actionable moves that translate strategic intent into measurable operational outcomes. First, invest in interoperable data platforms and decision-support tools that enhance the clinical utility of genomic findings and reduce clinician cognitive load. These platforms should support standardized reporting, integrate with electronic health records, and provide concise, actionable interpretations that clinicians can apply directly to treatment decisions. Second, develop modular evidence strategies that combine analytical validation with real-world performance data to satisfy both regulatory requirements and payer demands while enabling iterative refinement of clinical utility claims.

Third, strengthen supply chain resilience by diversifying suppliers and exploring regional manufacturing partnerships for critical components and reagents, thereby reducing exposure to policy-driven cost disruptions. Fourth, pursue targeted partnerships with therapeutic developers to co-develop companion diagnostics, ensuring alignment between assay design and clinical trial endpoints. Fifth, tailor commercial models to end-user needs by offering flexible laboratory solutions, from centralized reference services to distributed testing models supported by robust quality assurance and training programs. Finally, embed health economics and outcomes research early in product development to articulate value to payers and providers, facilitating more rapid reimbursement discussions and clinical uptake.

By executing these initiatives in an integrated fashion, organizations can accelerate clinical adoption, protect margin, and create durable differentiation within the molecular oncology diagnostics ecosystem.

A transparent and rigorous research methodology combining primary stakeholder interviews, secondary literature synthesis, and scenario-based analytical validation

The research methodology underpinning these insights combines evidence synthesis, stakeholder engagement, and rigorous analytical vetting to ensure relevance and reliability. Primary engagement included structured interviews with clinical oncologists, laboratory directors, diagnostic developers, procurement leaders, and regulatory advisors to capture firsthand perspectives on clinical workflows, validation expectations, and purchasing drivers. Secondary analysis incorporated peer-reviewed scientific literature, clinical guideline updates, regulatory publications, and case studies of operational implementations to contextualize primary findings and identify emergent technological trends.

Analytic approaches emphasized cross-validation of qualitative inputs with documented clinical pathways and regulatory guidance to reduce the risk of anecdotal bias. The methodology prioritized transparency in assumptions and traceability of sources, and applied scenario-based reasoning to explore how policy shifts or technological advancements could alter implementation timelines and stakeholder incentives. Wherever possible, methodological rigor included explicit criteria for evaluating assay performance characteristics, evidence tiers required for clinical utility claims, and operational prerequisites for laboratory integration.

This structured approach yields insights that are rooted in practical clinicopathologic realities and are sensitive to the operational constraints of laboratories and health systems. It supports decision-making by linking technical performance attributes to clinical workflows and reimbursement dynamics, enabling stakeholders to design evidence strategies and implementation plans that align with real-world needs.

Synthesis of strategic priorities that connect analytic rigor, clinical integration, and operational resilience to maximize clinical and commercial impact

In conclusion, molecular oncology diagnostics sit at the intersection of technological possibility and clinical necessity. The path to meaningful impact demands more than incremental assay improvements; it requires integrated solutions that align analytic performance with clinician workflows, evidence strategies, supply chain resilience, and payer expectations. Organizations that embrace interoperable data platforms, modular evidence generation, and strategic partnerships with therapeutic developers will be best positioned to translate genomic insights into routine clinical decisions.

Operational resilience and market agility are equally essential, particularly in the face of policy-driven cost adjustments and supply chain pressures that can affect assay continuity and pricing dynamics. Tailoring commercial models to end-user realities, investing in health economic evidence, and prioritizing clinical utility in diverse patient populations are practical steps that will accelerate adoption and sustain long-term value. Ultimately, diagnostic providers that deliver clear, actionable, and reproducible results within clinician workflows will achieve the greatest clinical and commercial impact, strengthening oncology care and improving patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molecular Oncology Diagnostics Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Molecular Oncology Diagnostics Market, by Technology

  • 9.1. Fluorescence In Situ Hybridization
  • 9.2. Immunohistochemistry
  • 9.3. Microarray
  • 9.4. Next Generation Sequencing
    • 9.4.1. Targeted Sequencing
      • 9.4.1.1. Comprehensive Panel
      • 9.4.1.2. Hotspot Panel
    • 9.4.2. Whole Exome Sequencing
    • 9.4.3. Whole Genome Sequencing
  • 9.5. Real Time PCR

10. Molecular Oncology Diagnostics Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Leukemia
  • 10.4. Lung Cancer
  • 10.5. Prostate Cancer

11. Molecular Oncology Diagnostics Market, by Sample Type

  • 11.1. Plasma Based
  • 11.2. Saliva & Urine
  • 11.3. Tissue Based
  • 11.4. Whole Blood

12. Molecular Oncology Diagnostics Market, by Application

  • 12.1. Companion Diagnostics
  • 12.2. Early Detection
  • 12.3. Personalized Medicine
  • 12.4. Prognosis & Monitoring
  • 12.5. Research Use

13. Molecular Oncology Diagnostics Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals & Clinics
  • 13.3. Pharmaceutical & Biotech Companies
  • 13.4. Research Institutes

14. Molecular Oncology Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Molecular Oncology Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Molecular Oncology Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Molecular Oncology Diagnostics Market

18. China Molecular Oncology Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Bayer AG
  • 19.8. Becton, Dickinson and Company
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Biocartis NV
  • 19.11. Biocept, Inc.
  • 19.12. BIOMERIEUX SA
  • 19.13. Danaher Corporation
  • 19.14. DiaSorin Molecular LLC
  • 19.15. Enzo Biochem, Inc.
  • 19.16. Exact Sciences Corporation
  • 19.17. F. Hoffmann-La Roche Ltd
  • 19.18. GenMark Saglik
  • 19.19. Guardant Health, Inc.
  • 19.20. Hologic, Inc.
  • 19.21. Illumina Inc.
  • 19.22. Leica Biosystems Nussloch GmbH
  • 19.23. Myriad Genetics, Inc.
  • 19.24. NeoGenomics Laboratories
  • 19.25. OncoCyte Corporation
  • 19.26. PathAI, Inc.
  • 19.27. Personal Genome Diagnostics Inc.
  • 19.28. QIAGEN N.V.
  • 19.29. Siemens AG
  • 19.30. Sysmex Asia Pacific Pte Ltd.
  • 19.31. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 190. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 191. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 217. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 226. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 227. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)